Compare KSCP & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | KLRS |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4M | 46.0M |
| IPO Year | 2022 | N/A |
| Metric | KSCP | KLRS |
|---|---|---|
| Price | $4.03 | $8.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $16.67 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 385.9K | 49.4K |
| Earning Date | 03-30-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,610,000.00 | N/A |
| Revenue This Year | $9.63 | N/A |
| Revenue Next Year | $31.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.50 | N/A |
| 52 Week Low | $2.45 | $2.14 |
| 52 Week High | $10.14 | $12.90 |
| Indicator | KSCP | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 51.63 |
| Support Level | $3.45 | $8.80 |
| Resistance Level | $3.98 | $10.28 |
| Average True Range (ATR) | 0.28 | 0.76 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 63.21 | 43.86 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.